Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02826382 · ClinicalTrials.gov registry record · Early Phase 1
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
A Early Phase 1 study, sponsored by Five Eleven Pharma.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT02826382 is a Early Phase 1 study that has completed, run by Five Eleven Pharma. The registered enrollment target is 14 participants.
The verdict
NCT02826382, a Early Phase 1 study, has completed, sponsored by Five Eleven Pharma.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
A phase1 study to demonstrate \[68Ga\]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
Interventions
- DRUG [68Ga]P15-041
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2022-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02826382
The ClinicalTrials.gov registry entry for NCT02826382 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Five Eleven Pharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [68Ga]P15-041 is the first listed.
NCT02826382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02826382 about?
NCT02826382 is a clinical study titled "Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041". A phase1 study to demonstrate \[68Ga\]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
What is the current status of trial NCT02826382?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2016-09-20. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT02826382?
The interventions under investigation include: [68Ga]P15-041 (DRUG).
Who is sponsoring clinical trial NCT02826382?
This trial is sponsored by Five Eleven Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.